Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Light-Controlled RNA Release for Gene Therapy
2026-10-07
A 2026 Trends in Biotechnology study describes a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates therapeutic gene expression at the level of translation. Evidence from mammalian cells and mouse disease models suggests that LIRP can provide temporally controllable transgene activity across liver-, skin-, and eye-relevant applications, although clinical translation remains untested.
-
B3465: α2-Adrenergic Receptor Evidence
2026-10-07
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is examined as an α2-adrenergic receptor agonist through the lens of immune-context-dependent evidence. This article distinguishes direct tumor-cell effects from CD8+ T-cell and TCR-associated mechanisms while defining the study’s translational limits.
-
Bifendate in Acute Liver Injury: Multiomics Evidence
2026-10-06
Talifu et al. used co-expression networks, transcriptomics, and proteomics to compare how bifendate and muaddil sapra affect molecular modules in a preclinical acute liver injury model. The study supports a systems-level view of DDB-associated responses, while its model and association-based analyses limit direct conclusions about human efficacy or clinical mechanism.
-
HOBt in Medicinal Chemistry: Evidence and Limits
2026-10-05
A source-grounded overview of HOBt in amide bond formation, using a glucagon receptor antagonist study to distinguish reagent utility from downstream biological evidence, while examining peptide synthesis applications, evidence strength, and research limitations.
-
Cy5 Amine (Non-Sulfonated): Product Overview
2026-10-05
Cy5 amine (non-sulfonated), SKU A8143, is a supplier-described amine-functionalized cyanine dye for research labeling applications. No matched paper evidence was provided, so its stated specifications and application scope should not be treated as independently validated performance.
-
HOBt in Peptide Coupling: Evidence and Limits
2026-10-03
HOBt is widely associated with amide bond formation and minimizing epimerization in peptides. This overview examines its conceptual chemistry context, its documented use in a 2015 glucagon receptor antagonist study, and the limits of inferring reagent performance from medicinal-chemistry outcomes.
-
Mianserin HCl: 5-HT2 Assay Workflows
2026-10-02
Mianserin HCl supports controlled studies of 5-HT2 receptor signaling, neuronal phenotypes, cyclodextrin-enabled cytotoxicity, and antipathogenic activity. This practical guide connects the compound’s receptor pharmacology with reproducible dosing, assay design, and troubleshooting strategies.
-
3-Deazaadenosine for Methylation & Viral Models
2026-10-01
3-Deazaadenosine is a mechanistically useful S-adenosylhomocysteine hydrolase inhibitor for separating methylation-dependent effects from gene-specific perturbations. This workflow-focused guide covers inflammatory cell models, preclinical antiviral research, formulation, assay design, and troubleshooting.
-
Propranolol Research Workflows and Troubleshooting
2026-10-01
Build reproducible Propranolol experiments spanning cardiovascular regulation, emotional memory modulation, essential tremor research, and metabolic assays. This guide combines formulation controls, functional endpoints, dose-screening logic, and troubleshooting for a non-selective β-adrenergic receptor blocker.
-
DDM for Dynamic Membrane Protein Structures
2026-09-30
Explore how n-Dodecyl-β-D-maltoside (DDM) can support membrane protein structural studies without disguising conformational heterogeneity. This guide connects detergent chemistry with recent full-length αvβ3 integrin cryo-EM findings and practical assay design.
-
Transcription Condensates and Genome Stability
2026-09-30
Marmolejo et al. identify a cell-cycle timer that forms transcription condensates at histone locus bodies during the G1/S transition and removes them in mid-S phase through ATR-CHK1 signaling. The study connects condensate resolution with linker histone H1.1 control and genome protection, offering a mechanistic framework for understanding replication-transcription coordination.
-
3X FLAG Peptide for Mechanistic Assays
2026-09-29
The 3X (DYKDDDDK) Peptide is more than a high-sensitivity epitope reagent: it can help separate protein abundance, interaction, and degradation in mechanistic assays. This guide develops an assay-design framework around STAT2–NS5 biology, metal sensitivity, purification, and structural workflows.
-
HOBt (1-Hydroxybenzotriazole) in Reliable Workflows
2026-09-29
This scenario-based guide explains how HOBt (1-Hydroxybenzotriazole), SKU A7025, supports controlled amide bond formation and helps protect stereochemical integrity before compounds enter cell viability or cytotoxicity assays. It separates upstream synthesis benefits from assay-specific validation, with practical storage, solubility, optimization, and vendor-selection guidance.
-
KIR2.1 Inhibition in Pulmonary Vascular Remodeling
2026-09-28
The reference study identifies KIR2.1 as a regulator of pulmonary artery smooth muscle cell proliferation and migration through the TGF-β1/SMAD2/3 pathway. Using a monocrotaline pulmonary hypertension model and PDGF-BB-stimulated human cells, the authors show that pharmacological KIR2.1 inhibition suppresses remodeling-associated phenotypes and reduces OPN and PCNA expression.
-
Troglitazone: PPARγ Agonist Research Guide
2026-09-28
Troglitazone is a PPARγ agonist used in research on nuclear-receptor signaling and lipid and glucose metabolism. Product information also describes renal-carcinoma cell findings, but the cited SPP1 tumor-macrophage study does not establish troglitazone as an SPP1 modulator.